Vitamin-Aspirin-Prednisolone Therapy for Miscarriage Associated with Anticardiolipin Antibody: Clinical Study

Yong-Chol Hong; Mi-Yong Paek; Hye-Son Jon; Hyon-Saeng Ju; Un-Hyang Pak

Abstract

Objective: To find pathogenesis of miscarriage associated with anticardiolipin antibody and to make reasonable therapy for the diseases. Methods: Blood coagulation findings, malondialdehyde volume are evaluated and those variations were observed with Vitamin–Aspirin–Prednisolone therapy. And clinical and laboratory findings, pregnancy outcomes were analyzed and relationship between medicine combined therapy and other factors (ages, attack period of disease, miscarriage times, and body mass index) is observed. Results: In anticardiolipin antibody positive group APTT and PT were 36.5  2.4s and 15.4  1.1s, respectively, Fbg was 229.2  14.4 mg/dl, FDP was 11.7  1.6g/mL, PAR was 82.3  2.5%, malondialdehyde volume was 8.71  0.43 nmoL/ml. In treatment application 20 days Fbg was 302.0  16.3 mg/dl, FDP was 6.2  1.2g/mL, malondialdehyde volume was 6.73  0.66 nmoL/ml. In treatment pause 20 days PAR was 81.4  3.6%. In study group, abortion rate was 10.0%, term labor rate and pregnancy maintenance rate were 85.0% and 90.0%, respectively, and preterm labor rate was 5.0%. In miscarriage times 3  group effective ratio depended on miscarriage time in medicine combined therapy was 42.9%. In body mass index, 24.1  group effective ratio depended on body mass index in medicine combined therapy was 42.9%. Conclusion: In anticardiolipin antibody positive patients, coagulation and platelet system were activated and malondialdehyde volume was increased. And, then, it was reasonable to repeat application for 20 days and pause for 10 days of VAP therapy.

Abstract

Keywords